

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE SUBOXONE (BUPRENORPHINE
HYDROCHLORIDE AND NALOXONE)
ANTITRUST LITIGATION**

**MDL NO. 2445
13-MD-2445**

THIS DOCUMENT RELATES TO:,

Wisconsin, et al. v. Indivior Inc. et al.
Case No. 16-cv-5073

**STATE OF WISCONSIN
By Attorney General Brad D. Schimel, et al.**

CIV. A. NO. 16-5073

Plaintiffs,

v.

**INDIVIOR INC. f/k/a RECKITT BENCKISER
PHARMACEUTICALS, INC., et al.**

Defendants.

ORDER

AND NOW, this 19th day of February, 2021, upon consideration of **(1)** Defendant Indivior’s Phase II Motion to Exclude Certain of the Opinions of Russell Lamb, Ernst Berndt, Rena Conti, Eric Emch, and the Pricing-Related Opinions of Laurence Westreich, and Yvonne Tso (MDL No. 13-2445, Doc. No. 661) and Plaintiffs’ Response (MDL No. 13-2445, Doc. No. 671); **(2)** Defendant Aquestive Therapeutics, Inc.’s Motion to Exclude Dr. Ernst Berndt (MDL No. 13-2445, Doc. No. 660; Civ. A. No. 16-5073, Doc. No. 415) and the State Plaintiffs’ Response (MDL No. 13-2445, Doc. No. 674; Civ. A. No. 16-5073, Doc. No. 424); and **(3)** the Direct Purchaser Plaintiffs’ Motion for Leave to File an *Amicus* Brief in Opposition to Defendant Aquestive’s Motion to Exclude Dr. Berndt (Civ. A. No. 16-5073, Doc. No. 425) and Aquestive’s Response (Civ. A. No. 16-5073, Doc. No. 428), it is hereby **ORDERED** that:

1. Indivior's Phase II Motion to Exclude (MDL No. 13-2445, Doc. No. 661) is **DENIED** as set forth in the Court's accompanying Memorandum Opinion.
2. Aquestive's Motion to Exclude (MDL No. 13-2445, Doc. No. 660; Civ. A. No. 16-5073, Doc. No. 415) is **DENIED** as set forth in the Court's accompanying Memorandum Opinion.
3. The Direct Purchaser Plaintiffs' Motion for Leave to File an *Amicus* Brief (Civ. A. No. 16-5073, Doc. No. 425) is **DENIED AS MOOT**.

BY THE COURT:

/s/ Mitchell S. Goldberg
MITCHELL S. GOLDBERG, J.